|
Patent landscape, scope, and claims: |
US Patent 8,669,281 Scope, Claims, and U.S. Patent Landscape for the Covered Compound and Compositions
US Patent 8,669,281 claims (i) a chemical entity defined by a structural formula and (ii) pharmaceutical compositions containing that entity (and salt forms). Claims 1 and 3 are product claims to compounds by formula, while claims 2 and 4 are composition claims to pharmaceutical compositions that contain the claimed compound (including pharmaceutically acceptable salts). Based on the claim set provided, the patent’s practical scope is concentrated in drug substance structure coverage and formulation coverage that is tied directly to the claimed compound, rather than method-of-use, device, or broad manufacturing/process claims.
What does US Patent 8,669,281 claim: compounds by formula and what is the composition scope?
Claim 1 and Claim 3: what is the “compound having the formula” coverage
- Claim 1: “A compound having the formula … or a pharmaceutically acceptable salt thereof.”
- Claim 3: “A compound having the formula …” (with no additional wording beyond what is shown in the excerpt you provided), which indicates a second structural formula that is independently claimed as a compound (and is typically read as another molecule or closely related analog defined by a distinct structural expression).
Scope implication (product coverage):
- These are structure-defined compound claims. Enforceability and infringement analysis typically hinge on whether an accused molecule falls within the structural boundaries of each claimed formula.
- The inclusion of “pharmaceutically acceptable salt thereof” extends coverage to salt forms of the exact chemical entity (salt identity and acceptable salt status can matter in litigation, but the claim text is written to encompass them).
Claim 2 and Claim 4: what is covered in “pharmaceutical composition comprising”
- Claim 2: “A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof.”
- Claim 4: “A pharmaceutical composition comprising a compound of claim 3.”
Scope implication (formulation coverage):
- These composition claims are tied to the compound claims. In practice, they cover formulations where the active is the claimed compound (or its salt).
- The claim language provided does not specify:
- routes of administration (oral, topical, parenteral),
- dosage form (tablet, capsule, injectable, etc.),
- excipients,
- drug-to-excipient ratios,
- controlled-release or specific formulation technology.
- As written, the composition coverage is typically broad as to dosage form and excipient selection, constrained mainly by the presence of the specific claimed compound (or salt).
How do US 8,669,281 claims map to infringement: what would an accused product need to look like?
Infringement on claim 1 vs claim 3
Because claims 1 and 3 are separate formula-defined compound claims, infringement analysis splits into two questions:
- Does the accused active ingredient match the chemical structure of claim 1?
- Does the accused active ingredient match the chemical structure of claim 3?
If either matches, the corresponding compound claim can be implicated. Salt coverage means an accused salt may also fall within coverage if the salt is a “pharmaceutically acceptable salt” of the claimed compound.
Composition infringement (claims 2 and 4)
A pharmaceutical product can infringe claim 2 or 4 if:
- the formulation contains the compound from claim 1 or claim 3, and
- the composition is a “pharmaceutical composition” as construed by the court (generally including compositions intended for therapeutic use, not merely chemical mixtures).
If an accused product uses a different active ingredient or a prodrug/analog not meeting the formula boundaries, the composition claims typically fail because they are derivative of the compound claims.
What is the likely breadth of the claims (and where is the patent weakest): salts, analogs, and formulation limitations
Broad elements
- The claims are not limited (in the excerpt provided) to a specific dosage form, administration route, or excipient profile.
- “Pharmaceutically acceptable salt” expands the protected subject matter beyond the free base/acid form.
Narrowing elements
- The claims are structure-limited. Variants that do not satisfy the exact formula are outside scope.
- If claim 3 is a distinct structure, it narrows coverage to whatever the distinct formula covers, not all analogs.
Where design-around is most feasible
Design-around is typically most feasible by changing:
- core scaffold atoms/bonding patterns required by the formula,
- stereochemistry if the formula imposes stereochemical constraints,
- substitution patterns not covered by the formula.
Since the claims as provided are formula-based, a chemical entity that does not match the claimed formula can avoid both the compound claims and the composition claims.
What patents commonly exist around a formula-compound claim: related U.S. filings, continuation coverage, and typical claim families
For formula-and-salt patents, related U.S. filings that often appear in the same estate include:
- continuations/divisionals targeting different dependent claim sets (e.g., specific substituents, specific salt forms, specific stereoisomers),
- polymorph/crystal form patents (if the compound is crystallized and characterized),
- solvate patents (hydrates/solvates),
- method-of-treatment (use) patents once the drug’s therapeutic area is established,
- intermediate or process patents (manufacturing routes),
- combination product patents (co-administration with other actives),
- formulation patents that add limitations (controlled release, bioavailability enhancement, particle size, etc.).
Given only the claim text you provided, the exact U.S. family members, their publication/filing dates, and their claim language cannot be reliably enumerated without referencing a specific public record for US 8,669,281 (specimen, assignee, and claim text beyond what was pasted).
How strong is US 8,669,281’s patent position: claim quality, enforceability, and typical invalidity/infringement vectors
Strength signals from the claim structure
- Product claims tied to a defined chemical structure often have clear infringement boundaries for a specific compound.
- Salt language can strengthen coverage against “salt switching” strategies.
Common vulnerabilities for formula-compound patents
While not inferable from the excerpt alone, standard litigation vectors for this claim type include:
- invalidity based on prior art chemical disclosures that anticipate or render obvious the claimed formula,
- lack of enablement or written description if the patent’s disclosure does not adequately teach preparation/use of the full claimed scope (especially relevant for formula language that could cover many possible variants),
- claim construction disputes around stereochemical meaning (if the formula includes stereochemistry or tautomers),
- disputes about whether an accused compound is a “pharmaceutically acceptable salt,” especially if a salt is not used clinically or lacks evidence of acceptability.
What is the Orange Book status of US 8,669,281: how would it appear for FDA-listed drugs?
This depends on:
- the identity of the active ingredient covered by the formula in claims 1 and 3,
- which listed drug product is connected to that active ingredient, and
- whether US 8,669,281 is actually listed in the Orange Book for that NDA/ANDA/BLA.
The claim excerpt does not include the active ingredient name or structural formula text in a readable form. Without the actual chemical identity, the Orange Book listing cannot be determined from the information provided.
When does exclusivity end versus patent expiration: what timeline governs generic risk?
Patent-expiration timing depends on:
- the filing date and term adjustments for US 8,669,281,
- whether any terminal disclaimers exist,
- whether patent term extension (PTE) was granted,
- whether the family has later-expiring continuation or related patents.
Exclusivity under the Hatch-Waxman regime depends on:
- the approval date of the NDA (or BLA) tied to the drug,
- the type of exclusivity (NCE, new clinical investigation, orphan, pediatric, etc.),
- whether exclusivity was triggered by the same active ingredient.
Those dates are not derivable from the claim excerpt alone.
What Paragraph IV challenges could target: which claims are most attackable in an ANDA/filing scenario?
For a patent like this (compound and composition claims), typical generic challenge targeting looks like:
- non-infringement by proving the generic active ingredient does not meet the formula,
- invalidity based on prior art anticipation or obviousness of the formula,
- and sometimes challenge of salt coverage if the generic uses a non-covered salt or challenges “pharmaceutically acceptable salt” interpretation.
A Paragraph IV notice would usually cite the asserted patent and allege invalidity and/or non-infringement. The most effective defense for the patentee is normally chemical-structure mapping to the claimed formula plus salt evidence.
How does US 8,669,281 compare with typical estates for the same drug class: what other IP usually matters at launch?
Even if US 8,669,281 blocks the compound and compositions, generic entry risk is usually managed through:
- additional compound/formulation patents with narrower but later-expiring terms,
- polymorph/solvate/process patents,
- method-of-use patents (if any exist),
- and FDA-related listing that ties patents to specific dosage forms.
In most real-world cases, the “block” on the Orange Book is seldom a single patent. The gap between the earliest compound patent expiration and later patent expirations often comes from continuation and formulation-specific patents.
Key constraints on using this claim excerpt for landscape work
The provided excerpt includes only claim numbers and generic placeholders for formulas, not:
- the compound identity,
- the assignee,
- the application number,
- the specification disclosure,
- family members,
- prosecution history,
- or the rest of the independent/dependent claim set.
Because those identifiers are required to reliably connect US 8,669,281 to:
- the exact estate,
- related continuations/divisionals,
- litigation involving the exact compound,
- Orange Book listings,
- and FDA approvals,
a complete U.S. patent landscape cannot be produced from the excerpt alone.
Key Takeaways
- US 8,669,281 is an active-ingredient structure patent with derivative composition claims: claims 1 and 3 cover compounds defined by formulas (and claim 1 includes pharmaceutically acceptable salts), while claims 2 and 4 cover pharmaceutical compositions containing those compounds/salts.
- The claims are likely broad as to formulation format but narrow as to chemical structure, making chemical structure design-around the primary generic risk lever.
- The patent landscape for this patent type typically includes related compound/formulation/process/polymorph/use patents, but identifying which ones belong to US 8,669,281 requires public bibliographic linkage to the patent’s disclosed compound and assignee.
FAQs
-
What is the difference between a compound claim and a composition claim in chemical patents?
A compound claim covers the specific molecule (and sometimes its salts) by structure, while a composition claim covers formulations that contain that molecule.
-
Can a generic avoid a salt-inclusive claim by using a different salt form?
Often yes if the alternative salt is not deemed a “pharmaceutically acceptable salt” of the claimed compound or if the salt is outside the claim’s proper construction, but this becomes fact- and evidence-driven.
-
How do stereochemistry constraints in a “formula” claim affect infringement?
If the formula effectively requires a particular stereochemical configuration or excludes others, an isomer switch can avoid literal infringement.
-
Do pharmaceutical composition claims require specific excipients or dosage forms?
If the claim does not specify excipients or dosage forms, scope is typically broad as long as the formulation qualifies as pharmaceutical and contains the claimed active.
-
What is the main invalidity theory for formula-defined compound patents?
Prior art anticipation or obviousness based on disclosures of the claimed structure (and close analogs) in the relevant time window.
References
No references can be provided from the information supplied because US 8,669,281’s bibliographic data, chemical identity, assignee, family members, and prosecution/litigation records were not included in the prompt.
More… ↓
⤷ Start Trial
|
